Finance

Lists
Outlook: 64.5% bullish·3.2% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,48 US$
+1,72%
(+0,025) 1D
1,43 US$
-3,05% (-0,045)
Pre-market
Closed: 11 ნოე, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
1,37 US$
High
1,48 US$
Low
1,30 US$
Mkt. cap
249,17 მლნ.
Avg. vol.
18,79 მლნ.
Volume
93,05 ათ.
52-wk high
2,72 US$
52-wk low
0,57 US$
EPS
-1,17 US$
Beta
1,71
Shares outstanding
103,40 მლნ.
No. of employees
112
Open
1,37 US$
High
1,48 US$
Low
1,30 US$
Mkt. cap
249,17 მლნ.
Avg. vol.
18,79 მლნ.
Volume
93,05 ათ.
52-wk high
2,72 US$
52-wk low
0,57 US$
EPS
-1,17 US$
Beta
1,71
Shares outstanding
103,40 მლნ.
No. of employees
112
News stories
From web sources and news partners
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOჟაკლინ შეა
Employees112
Founded1999
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current 1,48 US$
8,00 US$ (+442,37%)
Average
6,33 US$ (+329,15%)
Lowest
5,00 US$ (+238,98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
6,00 US$
+306,8%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
8,00 US$
+442,4%
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Upgraded
5,00 US$
+239%
11/02/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
13,00 US$
+781,4%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
13,33 მლნ.
10,26 მლნ.
14,07 მლნ.
10,83 მლნ.
Cost of revenue
13,33 მლნ.
10,26 მლნ.
14,07 მლნ.
10,83 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,88 მლნ.
7,22 მლნ.
7,88 მლნ.
7,80 მლნ.
Operating expense
7,88 მლნ.
7,22 მლნ.
7,88 მლნ.
7,80 მლნ.
Total operating expenses
21,21 მლნ.
17,48 მლნ.
21,95 მლნ.
18,62 მლნ.
Operating income
-21,21 მლნ.
-17,48 მლნ.
-21,95 მლნ.
-18,62 მლნ.
Other non operating income
-24,27 მლნ.
21,17 მლნ.
4,14 მლნ.
12,73 მლნ.
EBT including unusual items
-45,50 მლნ.
3,76 მლნ.
-19,68 მლნ.
-6,01 მლნ.
EBT excluding unusual items
-45,52 მლნ.
3,75 მლნ.
-19,48 მლნ.
-5,53 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45,50 მლნ.
3,76 მლნ.
-19,68 მლნ.
-6,01 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,87
-0,28
-0,31
-0,24
Interest and investment income
552,11 ათ.
449,34 ათ.
439,59 ათ.
363,85 ათ.
Interest expense
-
-
-
-
Net interest expenses
552,11 ათ.
449,34 ათ.
439,59 ათ.
363,85 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,86 მლნ.
-17,14 მლნ.
-21,63 მლნ.
-18,30 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები